BioPharmSignal logoBioPharmSignal

Biotech News

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

Ascendis Pharma (ASND)Ascendis PharmaCompany update

COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior Notes due 2028 (the “notes”) (CUSIP No. 04351P AD3 / ISIN No.

Related news

ASNDAscendis Pharma2026-08-06 20:01 EST

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

ASNDAscendis Pharma2026-06-26 20:01 EST

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

View all latest news

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

ASNDAscendis Pharma2026-08-13 11:30 EST

Ascendis Pharma Reports Second Quarter 2026 Financial Results

ASNDAscendis Pharma2026-08-06 20:01 EST

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

ASNDAscendis Pharma2026-08-06 12:00 EST

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

ASNDAscendis Pharma2026-06-30 12:30 EST

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

ASNDAscendis Pharma2026-06-26 20:01 EST

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

Stock data

Close
253.29 USD
Market cap
13.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States